PHARMACIES LATEST TARGET TO END PAIN MEDS DIVERSION
A Special Bulletin
By Bernard M. Cassidy
FORT LAUDERDALE, FL (October 12, 2011) The State of Florida and DEA, after spending the last two years dedicating substantial resources to eliminating so called “pill mills” have now turned considerable attention to pharmacies, particularly pharmacies associated with pain management clinics, and targeting pharmacies dispensing of what is perceived as large quantities of opioids such as oxycodone.
This latest law enforcement initiative aimed at pharmacies is in part the result of the shift of distribution of opioids from physician dispensers to pharmacies and from the fact that the DEA and State have been pretty successful shutting down some of what were perceived as the worst pill mills. As with other enforcement actions, criminal prosecutions as well as regulatory actions are sure to follow.
DOH inspections of pharmacies in the State of Florida are going to be increasingly difficult and exacting; and violations previously glossed over and cited on an inspection report for correction are now forming the basis of licensing complaints. This expected uptick in pharmacy scrutiny is another piece of the law enforcement effort to curtail Florida's prescription pain medication diversion epidemic. New statutes have made disciplinary sanctions for failure to properly review and validate prescriptions much more pronounced and has made due diligence by all drug suppliers mandatory.
Florida is also going to focus more heavily on the backgrounds of applicants for pharmacy licenses and subject them to much greater scrutiny. Under new laws, pharmacies and pharmacists are now responsible for reporting of doctor shopping within 24 hours. With the mandatory reporting of controlled substance prescribing and dispensing now in effect, regulators will have a whole new well of information to analyze pharmacy practices.










WASHINGTON D.C. (May 6, 2011) - U. S. Senator Sherrod Brown (D-OH) has introduced the
NEW ORLEANS, LOUISIANA - Thirty-one counts of Medicare and Medicaid fraud, totaling $12.5 million, were returned by a New Orleans Federal Grand Jury. Health Plus Consulting, Saturn Medical Group, New Millennium Medical Group, plus nine individuals were indicted on counts of health care fraud.
Early in the last decade the federal government began paying substantial attention to the marketing of drugs by manufacturers. Investigations and eventual settlements with Tap Pharmaceuticals ($875 million) and AstraZeneca ($350 million) paved the way for
Apparently, the message did not get through all the way. Recently there have been a number of settlements and even guilty pleas by pharmaceutical manufacturers, including AstraZeneca ($550 million), Pfizer ($2.3 billion) and Eli Lilly ($1.4 billion) related to other unlawful marketing practices. However, these cases involved the promotion of so called “off label” uses for their drugs, with some allegations kickbacks as well. The Pfizer settlement stems from an investigation instigated by six whistleblowers, who received $102 million from the settlements. The complaint charged that Pfizer sent doctors on all-expense-paid trips to resorts, gave out free massages, and paid kickbacks to doctors, to provide incentives to the doctors for them to prescribe drugs for off-label uses.
In an interesting suit filed against Amgen, the maker of Epogen, as well as two large dialysis clinic chains, Fresenius and Davita, a whistleblower alleges that salespeople for the drug company told clinic operators and physicians working there to prescribe specific dosage levels of the drug Epogen for patients based upon the maximum reimbursement under Medicare for the drug rather than actual patient needs.
Often, we hear that white collar crime is treated differently than other types of crime. However, it is often who commits white collar crime that brings about different treatment. I had a client indicted for fraud related to a DME. Monthly, he would send me articles about large DME companies paying large fines and false claims settlements for the same conduct he was alleged to have engaged in and asked the simple question, “Why am I supposed to go to jail and they don’t?”
In a case originating in the 1990’s, former pharmaceutical sales representatives for Johnson and Johnson (J&J) alleged 80% of a medication they marketed, Procrit, was used to commit Medicare Fraud; an amount equal to $3 billion for the company as a whole. Sales of the drug were promoted using several methods, all alleged to be illegal. One method was called “the spread.” The spread is the difference between the amount J&J would sell the drug using undisclosed discounts to physicians and hospitals and the amount those providers could claim and receive in reimbursement.






